{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:16:33Z","timestamp":1782537393912,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003347","name":"Fudan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22077018"],"award-info":[{"award-number":["22077018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.apsb.2023.07.008","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T21:33:10Z","timestamp":1689370390000},"page":"4906-4917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Structure-based design of novel heterocycle-substituted ATDP analogs as non-nucleoside reverse transcriptase inhibitors with improved selectivity and solubility"],"prefix":"10.1016","volume":"13","author":[{"given":"Li-Min","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-4473","authenticated-orcid":false,"given":"Christophe","family":"Pannecouque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-8890","authenticated-orcid":false,"given":"Erik De","family":"Clercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen-Er","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2023.07.008_bib1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Barr\u00e9-Sinoussi","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.07.008_bib2","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.6600519","article-title":"Isolation and transmission of human retrovirus","volume":"219","author":"Popovic","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.07.008_bib3","first-page":"1","article-title":"Global HIV & AIDS Statistics\u20142022 fact sheet","year":"2022","journal-title":"Joint United Nations Programme on HIV\/AIDS"},{"key":"10.1016\/j.apsb.2023.07.008_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2009.09.008","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989\u20122009)","volume":"85","author":"de B\u00e9thune","year":"2010","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2023.07.008_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/jmbi.1994.1665","article-title":"Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance","volume":"243","author":"Tantillo","year":"1994","journal-title":"J Mol Biol"},{"key":"10.1016\/j.apsb.2023.07.008_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jmb.2009.03.037","article-title":"Elucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulations","volume":"388","author":"Ivetac","year":"2009","journal-title":"J Mol Biol"},{"key":"10.1016\/j.apsb.2023.07.008_bib7","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1021\/acs.jmedchem.1c01758","article-title":"Contemporary medicinal chemistry strategies for the discovery and development of novel HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.07.008_bib8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.apsb.2019.11.010","article-title":"Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years","volume":"10","author":"Zhuang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.07.008_bib9","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.apsb.2022.08.017","article-title":"Development of fluorine-substituted NH2-biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: boosting the safety and metabolic stability","volume":"13","author":"Jin","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.07.008_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.apsb.2018.01.012","article-title":"Anti-retroviral drugs: current state and development in the next decade","volume":"8","author":"Zhang","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.07.008_bib11","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.apsb.2021.11.009","article-title":"Approved HIV reverse transcriptase inhibitors in the past decade","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.07.008_bib12","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1016\/j.apsb.2023.03.022","article-title":"Picomolar inhibitor of reverse transcriptase featuring significantly improved metabolic stability","volume":"13","author":"Sang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.07.008_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114581","article-title":"Discovery of novel biphenyl-substituted pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with promising oral bioavailability","volume":"240","author":"Zhao","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.07.008_bib14","doi-asserted-by":"crossref","first-page":"10257","DOI":"10.1021\/jm501100b","article-title":"Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals","volume":"57","author":"Vitaku","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.07.008_bib15","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1021\/acsinfecdis.0c00327","article-title":"Structure\u2012activity relationship exploration of NNIBP tolerant region I leads to potent HIV-1 NNRTIs","volume":"6","author":"Kang","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.apsb.2023.07.008_bib16","doi-asserted-by":"crossref","first-page":"15726","DOI":"10.1021\/acs.jmedchem.0c01372","article-title":"Antitubercular and antiparasitic 2-nitroimidazopyrazinones with\u00a0improved potency and solubility","volume":"63","author":"Ang","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.07.008_bib17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.bmcl.2013.12.070","article-title":"Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses","volume":"24","author":"C\u00f4t\u00e9","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2023.07.008_bib18","first-page":"1","article-title":"Perspectives on green synthesis and catalysis","volume":"1","author":"Kim","year":"2020","journal-title":"Green Synth Catal"},{"key":"10.1016\/j.apsb.2023.07.008_bib19","article-title":"Structure-directed expansion of biphenyl-pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with significantly improved potency and safety","author":"Zhao","year":"2023","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.apsb.2023.07.008_bib20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.bmc.2018.12.039","article-title":"Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs","volume":"27","author":"Wang","year":"2019","journal-title":"Bioorg Med Chem"},{"issue":"Suppl 2","key":"10.1016\/j.apsb.2023.07.008_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0213-005X(09)73216-1","article-title":"Etravirine drug interactions","volume":"27","author":"P\u00e9rez","year":"2009","journal-title":"Enferm Infecc Microbiol Cl\u00edn"},{"key":"10.1016\/j.apsb.2023.07.008_bib22","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1021\/acs.jmedchem.0c00117","article-title":"Structure-based bioisosterism yields HIV-1 NNRTIs with improved drug-resistance profiles and favorable pharmacokinetic properties","volume":"63","author":"Kang","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.07.008_bib23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1358\/dot.2020.56.2.3109966","article-title":"Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection","volume":"56","author":"Talwani","year":"2020","journal-title":"Drugs Today"},{"key":"10.1016\/j.apsb.2023.07.008_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112290","article-title":"hERG toxicity assessment: useful guidelines for drug design","volume":"195","author":"Garrido","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.07.008_bib25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/med.21445","article-title":"Development of safe drugs: the hERG challenge","volume":"38","author":"Kalyaanamoorthy","year":"2018","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2023.07.008_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/cid\/ciaa822","volume":"73","author":"Orkin","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.apsb.2023.07.008_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114939","article-title":"Structure-guided design of novel HEPT analogs with enhanced potency and safety: from isopropyl-HEPTs to cyclopropyl-HEPTs","volume":"246","author":"Zhou","year":"2023","journal-title":"Eur J Med Chem"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221138352300271X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221138352300271X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:06:13Z","timestamp":1761930373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221138352300271X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S221138352300271X"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2023.07.008","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-based design of novel heterocycle-substituted ATDP analogs as non-nucleoside reverse transcriptase inhibitors with improved selectivity and solubility","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2023.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}